The Immunity journal has published a study exploring possible pharmacological targets in leukocytes. The study revealed CBP/p300 histone acetyltransferase inhibitors increased leukocyte count in bone marrow, blood, and tissues, without adverse side effects. The study used A485 in mice, which accumulated in selected tissues; coincidentally, leukocyte count increased. The research raised queries about the drug’s clinical use, the propriety of this medication over G-CSF, and the need for further research, such as how the drug can limit bacterial or viral sepsis. It also unveiled a role for adrenocorticotropic hormones in homeostasis and G-CSF activity.
Source link
Small-molecule A485 mobilizes white blood cells on demand
